Skip to main content
OpenTrials
Completed

NCT Number: NCT00370266

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Branch Retinal Vein Occlusion Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Macular Degeneration Macular Edema Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Retinal Neovascularization Retinal Vein Occlusion Thrombosis Vascular Diseases Venous Thrombosis

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alireza Ramezani, MD

Tehran, Tehran Province, 16666, Iran

About this study

Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic macular edema due to vein occlusion and preventive effect on neovascularization. Hypothetically, prevention of macular derangement by reducing the amount of edema from early phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To our knowledge, no prospective randomized clinical trial, considering both macular changes and preventive effect on neovascularization has been published for intravitreal triamcinolone in acute branch retinal vein occlusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eyes suffering from branch retinal vein occlusion with less than 2 months duration.

Exclusion criteria

  • Monocularity,
  • Previous intraocular surgery or laser therapy
  • Glaucoma or ocular hypertension
  • Significant media opacity
  • Existence of traction on the macula
  • Visual acuity ≥20/40
  • Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)

Treatment and study plan

Triamcinolone

Drug

Primary outcomes

  1. Central macular thickness

Secondary outcomes

  1. Visual acuity

  2. Retinal neovascularization

  3. Intraocular pressure

  4. Cataract progression

Sponsors and collaborators

Lead sponsor

Shahid Beheshti University of Medical Sciences

Other

Registry information

Important dates

Study start
2003
Primary completion
2007
Study completion
2007
First posted
Aug 31, 2006
Registry last updated
Jun 17, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.